Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
NVK-029 by Vyluma for Presbyopia: Likelihood of Approval
NVK-029 is under clinical development by Vyluma and currently in Phase I for Presbyopia. According to GlobalData, Phase I drugs...